COMMUNIQUÉS West-GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05/04/2024 - 13:02

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the [...]

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

05/04/2024 - 13:00

Company presentation and fireside chat on April 11th at 11:45 a.m. ET CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a [...]

Teladoc Health Board of Directors Announces Leadership Transition

05/04/2024 - 12:30

Jason Gorevic to depart the company, effective immediately CFO Mala Murthy appointed acting chief executive Teladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: [...]

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

05/04/2024 - 10:30

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies [...]

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

05/04/2024 - 08:08

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility [...]

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

05/04/2024 - 07:00

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytruda i (pembrolizumab). [...]

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

05/04/2024 - 06:34

CLOSED 6 BILLION DOLLAR SERIES B DEAL SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, April 4, 2024 by NeuroVigil, Inc., please note the contact information [...]

Ibogaine By David Dardashti Investigates Impact of Quantum Physics on April 8 Solar Eclipse

05/04/2024 - 05:37

A Unique Opportunity to Experience the Unprecedented Potential of Ibogaine Treatment Based on Quantum Electrodynamics MIAMI, April 04, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti has uncovered a unique [...]

Sirona Biochem Announces Close of Private Placement

05/04/2024 - 03:24

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (“ Sirona ”) has closed its private placement (Private [...]

Contineum Therapeutics Announces Pricing of Initial Public Offering

05/04/2024 - 03:02

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target [...]

Digicann Ventures Grants Restricted Share Units

05/04/2024 - 03:00

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD), a company focused on opportunities within and outside of the cannabis [...]

CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

05/04/2024 - 01:33

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 avr. 2024 (GLOBE NEWSWIRE) -- Ce document corrige et remplace le communiqué de presse diffusé le 4 avril à 16:30 heure de l'Est. Place [...]

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

05/04/2024 - 00:34

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

MESA LABS DECLARES QUARTERLY DIVIDEND

05/04/2024 - 00:24

LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $ [...]

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

04/04/2024 - 22:43

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024

04/04/2024 - 22:43

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/04/2024 - 22:30

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

04/04/2024 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

04/04/2024 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 avr. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]